SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer
Conditions:  Anatomic Stage IV Breast Cancer AJCC v8;  Breast Inflammatory Carcinoma;  Metastatic Triple-Negative Breast Carcinoma;  Prognostic Stage IV Breast Cancer AJCC v8 Interventions:  Drug: Carboplatin;  Biological: Pembrolizumab;  Genetic: Transferrin Receptor-Targeted Liposomal p53 cDNA Sponsors:  Northwestern University;  National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Genetics | Inflammatory Breast Cancer | Research